Plain-English translation of NCT06341543 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After a solid organ transplant, some patients develop CMV (a common virus) in their blood without feeling sick. This trial tests a new blood test called QuantiFERON-CMV that measures your immune system's ability to fight the virus. The goal is to help doctors decide whether you actually need antiviral medication or whether your body can control the virus on its own.
Not everyone with detectable CMV in their blood needs treatment—some people's immune systems naturally control it. Currently, doctors struggle to know who really needs antiviral drugs, which can be toxic and expensive. This study hopes the new blood test will identify which patients truly need treatment and which ones don't.
You likely qualify if…
You likely don't qualify if…
If you qualify, your doctor will offer you a chance to join within 48 hours of discovering your CMV infection. You'll have a blood sample taken for the QuantiFERON-CMV test. You will then be randomly assigned to one of two groups: one where your doctor sees the test result to help make treatment decisions, and one where your doctor follows standard guidelines without seeing the result. Your doctor will decide whether to give you antiviral treatment based on their group assignment and standard medical practice.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
France